156 related articles for article (PubMed ID: 9923549)
21. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Cao S; McGuire JJ; Rustum YM
Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
[TBL] [Abstract][Full Text] [Related]
22. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
23. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts.
Dalrymple SL; Becker RE; Isaacs JT
Prostate; 2007 May; 67(7):790-7. PubMed ID: 17373719
[TBL] [Abstract][Full Text] [Related]
24. Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines.
Rocchi P; Boudouresque F; Zamora AJ; Muracciole X; Lechevallier E; Martin PM; Ouafik L
Cancer Res; 2001 Feb; 61(3):1196-206. PubMed ID: 11221851
[TBL] [Abstract][Full Text] [Related]
25. Prostate carcinoma response to cytotoxic therapy: in vivo resistance.
Teicher BA; Kakeji Y; Ara G; Herbst RS; Northey D
In Vivo; 1997; 11(6):453-61. PubMed ID: 9509295
[TBL] [Abstract][Full Text] [Related]
26. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis.
Singh RP; Sharma G; Dhanalakshmi S; Agarwal C; Agarwal R
Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):933-9. PubMed ID: 14504208
[TBL] [Abstract][Full Text] [Related]
27. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.
Sirotnak FM; She Y; Lee F; Chen J; Scher HI
Clin Cancer Res; 2002 Dec; 8(12):3870-6. PubMed ID: 12473602
[TBL] [Abstract][Full Text] [Related]
28. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
29. Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signaling.
Wells A; Souto JC; Solava J; Kassis J; Bailey KJ; Turner T
Clin Cancer Res; 2002 Apr; 8(4):1251-7. PubMed ID: 11948140
[TBL] [Abstract][Full Text] [Related]
30. Effects of the polyamine analogues BE-4-4-4-4, BE-3-7-3, and BE-3-3-3 on the proliferation of three prostate cancer cell lines.
Jeffers L; Church D; Basu H; Marton L; Wilding G
Cancer Chemother Pharmacol; 1997; 40(2):172-9. PubMed ID: 9182840
[TBL] [Abstract][Full Text] [Related]
31. [Effects of suramin in combination with cisplatin on growth and metastasis of lung adenocarcinoma xenografts in mice].
Zhang P; He JB; Ou LW; Wang XH
Ai Zheng; 2006 Apr; 25(4):409-13. PubMed ID: 16613671
[TBL] [Abstract][Full Text] [Related]
32. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells.
Drees M; Dengler WA; Roth T; Labonte H; Mayo J; Malspeis L; Grever M; Sausville EA; Fiebig HH
Clin Cancer Res; 1997 Feb; 3(2):273-9. PubMed ID: 9815683
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.
Zhang Y; Ma Y; Lu HP; Gao JH; Liang CS; Liu CZ; Zou JT; Wang HQ
Chin Med J (Engl); 2008 Nov; 121(22):2284-9. PubMed ID: 19080333
[TBL] [Abstract][Full Text] [Related]
34. A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity.
London CA; Sekhon HS; Arora V; Stein DA; Iversen PL; Devi GR
Cancer Gene Ther; 2003 Nov; 10(11):823-32. PubMed ID: 14605668
[TBL] [Abstract][Full Text] [Related]
35. Characterization of a transplantable hormone-responsive human prostatic cancer xenograft TEN12 and its androgen-resistant sublines.
Harper ME; Goddard L; Smith C; Nicholson RI
Prostate; 2004 Jan; 58(1):13-22. PubMed ID: 14673948
[TBL] [Abstract][Full Text] [Related]
36. Ionizing radiation causes a dose-dependent release of transforming growth factor alpha in vitro from irradiated xenografts and during palliative treatment of hormone-refractory prostate carcinoma.
Hagan M; Yacoub A; Dent P
Clin Cancer Res; 2004 Sep; 10(17):5724-31. PubMed ID: 15355899
[TBL] [Abstract][Full Text] [Related]
37. Cyclopropane-containing polyamine analogues are efficient growth inhibitors of a human prostate tumor xenograft in nude mice.
Frydman B; Blokhin AV; Brummel S; Wilding G; Maxuitenko Y; Sarkar A; Bhattacharya S; Church D; Reddy VK; Kink JA; Marton LJ; Valasinas A; Basu HS
J Med Chem; 2003 Oct; 46(21):4586-600. PubMed ID: 14521420
[TBL] [Abstract][Full Text] [Related]
38. 9-Aminocamptothecin: a topoisomerase I inhibitor with preclinical activity in prostate cancer.
de Souza PL; Cooper MR; Imondi AR; Myers CE
Clin Cancer Res; 1997 Feb; 3(2):287-94. PubMed ID: 9815685
[TBL] [Abstract][Full Text] [Related]
39. Antitumor activity of N1,N11-bis(ethyl)norspermine against human melanoma xenografts and possible biochemical correlates of drug action.
Porter CW; Bernacki RJ; Miller J; Bergeron RJ
Cancer Res; 1993 Feb; 53(3):581-6. PubMed ID: 8425191
[TBL] [Abstract][Full Text] [Related]
40. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate.
Samid D; Shack S; Myers CE
J Clin Invest; 1993 May; 91(5):2288-95. PubMed ID: 8486788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
